Who owns sirolimus patent?

Who owns the sirolimus patents today?
Sirolimus (rapamycin) is patented by Pfizer Inc. and its subsidiaries. The company holds the key composition‑of‑matter and formulation patents that were first granted in the 1980s and 1990s. Pfizer retains ownership of the original patents, and it licenses manufacturing rights to a few contract manufacturers under strict agreements. [1]

When did the original sirolimus patents expire?
The main U.S. composition‑of‑matter patents filed in the mid‑1980s expired between 2004 and 2009, after the 17‑year patent term ran its course. Because the active‑ingredient patents have lapsed, generic manufacturers are free to produce sirolimus, provided they meet regulatory standards. [1]

Can other companies produce sirolimus now?
Yes. After the expiration of Pfizer’s core patents, generic and biosimilar manufacturers can enter the market. The U.S. FDA has approved several generic versions of sirolimus for organ‑transplant rejection and other indications. However, each generic must establish bioequivalence to the reference product and comply with Good Manufacturing Practice (GMP) requirements. [1]

Why did Pfizer originally hold the sirolimus patents?
Pfizer secured the patents when it acquired rights from the Medical Research Council of the United Kingdom, the discoverers of rapamycin. By holding the patents, Pfizer could control pricing, licensing, and commercial distribution of sirolimus for nearly a decade. This strategy is common for high‑value biologic and immunosuppressive drugs. [1]

Are there still active patents on sirolimus derivatives?
Yes. While the core sirolimus patents have expired, Pfizer and other companies hold newer patents on modified formulations (e.g., extended‑release capsules) and on specific indications that use sirolimus in combination therapies. These later‑filed patents can still protect certain aspects of the drug’s commercial use. [1]

How does patent expiration affect pricing?
Once the core patents expired, the entry of generics drove sirolimus prices down significantly. According to pricing data, the average wholesale price dropped from roughly $8,000 per month for the brand‑name product to around $1,200–$1,500 for generic formulations. Market competition continues to pressure prices, but the brand‑name product remains used for specific transplant protocols. [1]

What should clinicians consider when prescribing sirolimus?
Prescribers need to verify that the generic product meets FDA bioequivalence standards and to monitor patients for typical adverse effects such as hyperlipidemia, leukopenia, and delayed wound healing. The choice between brand and generic often depends on insurance coverage and institutional formulary policies. [1]

Sources
[1] https://www.drugpatentwatch.com/patents/sirolimus